Arquer CEO Nadia Whittley Named Among Top 50 Female ‘Movers & Shakers’ in BioBusiness Report

Arquer Diagnostics Ltd (“Arquer”), a UK-based company focusing on the development of non-invasive cancer diagnostic tests today announced that CEO Nadia Whittley has been named among the top 50 ‘Movers & Shakers’ in BioBusiness 2018 report, compiled by BioBeat, an organization dedicated to connecting entrepreneurs with the leaders in biotech.

Now in its fifth year, The BioBeat Movers & Shakers report identifies women who are developing revolutionary bioscience products for healthcare, shaping entrepreneurial bioscience through investment, accelerating the innovation pipeline, transforming patient access to healthcare and supporting innovation from concept to market. Arquer CEO Nadia Whittley’s efforts have been recognized within the contributions to Science section of the report, joining a host of other female influencers who are making significant contributions to the UK biomedical community and economy.

The recent launch and commercialisation of the ADXBLADDER cancer diagnostic test and the restructuring of the Arquer Diagnostics business to streamline clinical, market access and commercial strategies were key achievements reflected in Nadia’s listing within this power list.

To read the full BioBeat 2018 Movers and Shakers report, please click this link here BioBeat 18 50 MS 151018 14.00

– ENDS –

About Arquer Diagnostics

Arquer Diagnostics (www.arquerdx.com) headquartered in Sunderland, United Kingdom, is a company focused on the development of non-invasive cancer diagnostic tests, based on the MCM5 (minichromosome maintenance protein) platform.  Arquer Ltd was launched in 2015, following a strategic decision to put into action the powerful research that had been conducted by a small enterprise, founded in 2005 by Nick Miller-Jones (UroSens). Since then, the company has amassed strong clinical data to support the launch of its first product ADXBLADDER, a bladder cancer diagnostic test, and is running a number of clinical trials to validate many other indications. Arquer is supported by first class international Medical Advisory Boards and together we are aiming at inspiring transformational change in the field of oncology diagnostics.

Contact: Arquer Diagnostics Ltd

T: +44 (0) 191 516 6765

E: info@arquerdx.com

www.arquerdx.com

Leave a Reply